Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of interleukin-17A inhibitors in patients with ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials
Authors
Keywords
-
Journal
CLINICAL RHEUMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-01-13
DOI
10.1007/s10067-020-05545-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases
- (2019) Kübra Bunte et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Biologic therapies targeting the interleukin ( IL )‐23/ IL ‐17 immune axis for the treatment of moderate‐to‐severe plaque psoriasis: a systematic review and meta‐analysis
- (2019) C.Y. Erichsen et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Adverse events with IL‐17 and IL‐23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta‐analysis of phase III studies
- (2019) N.D. Loft et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Relationship of work disability between the disease activity, depression and quality of life in patients with ankylosing spondylitis
- (2018) Sinem Sağ et al. JOURNAL OF BACK AND MUSCULOSKELETAL REHABILITATION
- IL-17 in the immunopathogenesis of spondyloarthritis
- (2018) Leonie S. Taams et al. Nature Reviews Rheumatology
- Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis
- (2018) Klaus Krüger et al. RHEUMATOLOGY INTERNATIONAL
- The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond
- (2018) Sayam Dubash et al. Expert Review of Clinical Immunology
- Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
- (2018) Désirée van der Heijde et al. LANCET
- Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
- (2018) Jürgen Braun et al. RHEUMATOLOGY
- Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor
- (2018) Atul Deodhar et al. Arthritis & Rheumatology
- Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective
- (2018) Ron Goeree et al. JOURNAL OF MEDICAL ECONOMICS
- Axial spondyloarthritis
- (2017) Joachim Sieper et al. LANCET
- 108. THE COST-EFFECTIVENESS OF SECUKINUMAB VERSUS TUMOUR NECROSIS FACTOR α INHIBITOR BIOSIMILARS FOR ANKYLOSING SPONDYLITIS IN THE UK
- (2017) Helena Marzo-Ortega et al. RHEUMATOLOGY
- Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study
- (2017) H. Marzo-Ortega et al. ARTHRITIS CARE & RESEARCH
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease
- (2016) Stephan R Targan et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
- (2016) Joachim Sieper et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study
- (2016) Jürgen Braun et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparative Effectiveness of Biologic Therapy Regimens for Ankylosing Spondylitis
- (2016) Chao Chen et al. MEDICINE
- Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials
- (2016) Sumit Kunwar et al. RHEUMATOLOGY INTERNATIONAL
- Cost-Effectiveness Analysis of Different Biologic Agents For Ankylosing Spondylitis Treatment In Russia
- (2016) D Fedyaev et al. VALUE IN HEALTH
- Global Prevalence of Spondyloarthritis: A Systematic Review and Meta-Regression Analysis
- (2016) Carmen Stolwijk et al. ARTHRITIS CARE & RESEARCH
- Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)
- (2016) Atul A. Deodhar et al. Arthritis & Rheumatology
- Long-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational study
- (2015) Xenofon Baraliakos et al. ANNALS OF THE RHEUMATIC DISEASES
- The IL-23–IL-17 axis in inflammatory arthritis
- (2015) Erik Lubberts Nature Reviews Rheumatology
- American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
- (2015) Michael M. Ward et al. Arthritis & Rheumatology
- The IL-23/IL-17 axis in psoriatic arthritis
- (2014) Erika Suzuki et al. AUTOIMMUNITY REVIEWS
- The Interleukin-17 Pathway in Psoriasis and Psoriatic Arthritis: Disease Pathogenesis and Possibilities of Treatment
- (2014) Marina Frleta et al. Current Rheumatology Reports
- Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
- (2013) Dominique Baeten et al. LANCET
- Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study
- (2012) Mark C Genovese et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutic potential
- (2012) Shu Zhu et al. CLINICAL SCIENCE
- In Vivo Peripheral Blood Proinflammatory T Cells in Patients with Ankylosing Spondylitis
- (2012) L. LIMON-CAMACHO et al. JOURNAL OF RHEUMATOLOGY
- Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis
- (2012) Craig Leonardi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enrichment of circulating interleukin-17-secreting interleukin-23 receptor-positive γ/δ T cells in patients with active ankylosing spondylitis
- (2011) Tony J. Kenna et al. ARTHRITIS AND RHEUMATISM
- Spondyloarthritis
- (2011) Maxime Dougados et al. LANCET
- Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response
- (2011) Heiner Appel et al. ARTHRITIS RESEARCH & THERAPY
- Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis
- (2010) Yang Mei et al. CLINICAL RHEUMATOLOGY
- Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
- (2010) W. Hueber et al. Science Translational Medicine
- Frequency and phenotype of peripheral blood Th17 cells in ankylosing spondylitis and rheumatoid arthritis
- (2009) Hui Shen et al. ARTHRITIS AND RHEUMATISM
- Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides
- (2008) Camilla Jandus et al. ARTHRITIS AND RHEUMATISM
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started